Status:
COMPLETED
Aprotinin in Neonates Undergoing Cardiopulmonary Bypass
Lead Sponsor:
Children's Healthcare of Atlanta
Conditions:
Cardiopulmonary Bypass
Congenital Defects
Eligibility:
All Genders
Up to 1 years
Brief Summary
This is a retrospective chart review study. The purpose of this study is to review our experience at Children's Healthcare of Atlanta in neonates receiving aprotinin. We will examine the specific outc...
Detailed Description
Aprotinin (Trasylol; Bayer Corporation, Pittsburgh, PA), a serine protease inhibitor isolated from bovine lung, is used intra-operatively during cardiac surgery to reduce bleeding. It is thought to wo...
Eligibility Criteria
Inclusion
- Neonates who underwent Cardiopulmonary Bypass (CPB) at Children's Healthcare of Atlanta between March 2004 and March 2007.
Exclusion
- All candidates who do not meet inclusion criteria.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT00469742
Start Date
April 1 2007
End Date
December 1 2008
Last Update
March 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322